Navigation Links
Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer
Date:12/16/2008

BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr. An comes to Epitomics from Merck Research Laboratories, where he was Director of Biologics Research. He has over 12 years of experience in drug discovery and development in the biotech and pharmaceutical industries, focusing on therapeutic antibody discovery, humanization and affinity maturation, preclinical and clinical development.

Epitomics, exclusive maker of RabMAb(R) monoclonal antibodies, is the commercial supplier of rabbit monoclonal antibodies, with customers around the world, including major biotechnology/pharmaceutical companies and academic research laboratories. With several recently issued industry-changing patents, Epitomics has established its proprietary RabMAb as a unique antibody technology with an excellent IP position. The addition of Dr. An further sets the stage for Epitomics to move aggressively into the human antibody therapeutic market starting with major pre-clinical work on multiple targets in 2009.

"Dr. An brings a wealth of knowledge and experience in antibody discovery, which he will leverage with Epitomics' strong technologies and innovation to generate a pipeline of best-in-class antibody therapeutics focusing on clinically proven targets for broad therapeutic indications. We are delighted that he joins the executive management team at such a decisive stage of the company's development," said Dr. Guo-Liang Yu, CEO of Epitomics.

"RabMAb(R) is a novel class of monoclonal antibodies which possess unique biological properties, including ultra-high affinity, diversity in epitope recognition, and high target specificity. Epitomics provides me with the opportunity to expand the healthcare promises of biologics by developing RabMAb as a major therapeutic antibody discovery platform. We have embarked on a journey to bring truly widespread antibody therapy to patients around the world," said Dr. Zhiqiang An.

Prior to joining Epitomics, Dr. An played a major role in the creation of Merck's biologics research department including the establishment of their antibody technology platform. In his tenure at Merck, Dr. An and his team initiated a large number of antibody discovery programs in diverse therapeutics areas. As a result, multiple antibodies were identified as development candidates and are currently at various stages of development.

Dr. An started his biotech/pharmaceutical career at Millennium Pharmaceuticals where he established one of the very first programs attempting biocombinatorial natural products drug discovery using microbial molecular genetics and engineering approaches. Dr. An is a frequently invited speaker at scientific conferences and various academic settings and has authored numerous patents, journal articles, review papers, and books, including 2006's "Handbook of Industrial Mycology" and a comprehensive treatise entitled "Therapeutic Antibodies - from Theory to Practice," which will be published in early 2009. He received a B.S. in Biology from Shanxi Agricultural University, an M.S. in Biology from Beijing Agricultural University, and a Ph.D. in Plant Pathology from University of Kentucky, Lexington. Dr. An had his postdoctoral training at University of Wisconsin-Madison.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb(R) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. (www.epitomics.com) is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, ... ... (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing ... companies interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):